Healthcare -
Biotechnology - NASDAQ - US
$ 11.1
0.892 %
$ 161 M
Market Cap
0.11
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Inhibrx Biosciences, Inc.
| Revenue | 200 K |
| Cost Of Revenue | 2.28 M |
| Gross Profit | -2.08 M |
| Operating Expenses | 332 M |
| Operating Income | -331 M |
| Other Expenses | -2.02 B |
| Net Income | 1.69 B |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0.2 | 1.8 | 2.2 | 7.1 | 12.8 | 9.1 | 7.5 | 8.0 | 6.7 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 2.3 | 1.2 | 2.8 | 2.7 | 73.5 | 47.9 | 33.5 | 25.5 | 17.0 |
| Gross Profit | (2.1) | 0.6 | (0.7) | 4.4 | (60.7) | (38.8) | (26.0) | (17.6) | (10.3) |
| OPERATING INCOME | |||||||||
| Operating Expenses | 331.6 | 219.8 | 131.3 | 83.7 | 80.3 | 52.8 | 37.0 | 27.7 | 18.6 |
| Selling, General and Administrative Expenses | 127.9 | 29.4 | 21.1 | 12.4 | 6.8 | 9.0 | 4.7 | 2.6 | 1.6 |
| Research and Development Expenses | 203.7 | 190.6 | 110.2 | 71.4 | 73.5 | 47.9 | 33.5 | 25.5 | 17.0 |
| Operating Income | (331.4) | (219.2) | (129.1) | (76.6) | (67.4) | (43.7) | (29.5) | (19.7) | (12.1) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 13.5 | 31.8 | 16.1 | 5.2 | 10.8 | 5.7 | 1.5 | 2.1 | 0 |
| Total Other Income | 2 019.0 | (20.5) | (29.9) | (5.2) | (8.2) | (6.8) | (1.4) | (2.1) | (0.7) |
| Pre-Tax Income | 1 687.6 | (239.7) | (145.2) | (81.8) | (75.6) | (50.5) | (30.9) | (21.8) | (12.9) |
| NET INCOME | |||||||||
| Tax Provision | 2 K | 3 K | 3 K | 2 K | 3 K | 0.9 | 96 K | 0.2 | (4.6) |
| Net Income | 1 687.6 | (241.4) | (145.2) | (81.8) | (75.6) | (51.4) | (31.2) | (19.4) | (8.3) |
| EPS | 114 | 5.12 | 3.62 | 2.15 | 2.99 | 1.41 | 1.15 | 0.68 | 0.23 |